Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 202

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

SMAD4 as a Prognostic Marker in Colorectal Cancer

Alazzouzi, Hafid, Alhopuro, Pia, Salovaara, Reijo, Sammalkorpi, Heli, Järvinen, Heikki, Mecklin, Jukka-Pekka, Hemminki, Akeseli, Schwartz, Simo, Aaltonen, Lauri A., Arango, Diego · 2005 · Clinical Cancer Research

Abstract

More than 50% of patients with Dukes C colorectal cancer have disease recurrence and die within 5 years after surgical removal of their primary tumor. It is currently not possible to distinguish patients with good and bad prognosis. SMAD4 is an important tumor suppressor gene that mediates transforming growth factor-β superfamily signaling and is located in chromosome 18q21, a region with frequent genetic losses in these tumors. Allelic imbalance in 18q has been linked to poor prognosis in a subset of colorectal cancer patients. Therefore, we generated a tissue microarray containing triplicate tumor samples from 86 Dukes C patients and used immunohistochemistry to assess the relative expression level of SMAD4 and its value as a prognostic marker. In addition, SMAD4 was screened for mutations and two polymorphic microsatellite markers were used to assess the presence of allelic imbalance in these tumors. Patients with tumors expressing high SMAD4 levels had significantly better overall (P < 0.025) and disease-free (P < 0.013) survival than patients with low levels. This identifies SMAD4 as a prognostic marker for Dukes C colorectal cancer. Although all tumors with absent SMAD4 staining showed allelic imbalance in 18q21, tumors with 18q21 allelic imbalance as a group showed no difference in SMAD4 levels compared with tumors without allelic imbalance, suggesting that additional mechanisms of SMAD4 down-regulation exist. In addition, although SMAD4 mutations were found in five tumors, they were not associated with shorter survival. In conclusion, the level of expression of SMAD4 was found to be a more sensitive marker than 18q21 allelic imbalance and SMAD4 mutations, which were of no prognostic significance for these patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-04-1458

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 202

Metadata

Authors
Alazzouzi, H., Alhopuro, P., Salovaara, R., Sammalkorpi, H., Järvinen, H., Mecklin, J.-P., Hemminki, A., Schwartz, S., Aaltonen, L. A., & Arango, D.
Venue
Clinical Cancer Research
Published
2005-04-01
Volume
11
Issue
7
Pages
2606-2611
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2148956245
Cited by
202
References
2
FWCI
5.68
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SMAD4 as a Prognostic Marker in Colorectal Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-04-1458
The paper
Alazzouzi, H., Alhopuro, P., Salovaara, R., Sammalkorpi, H., Järvinen, H., Mecklin, J.-P., Hemminki, A., Schwartz, S., Aaltonen, L. A., & Arango, D. (2005). SMAD4 as a Prognostic Marker in Colorectal Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-04-1458

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.